XRTX Company Profile and Key Details

XORTX Therapeutics Inc. last paid a dividend of 0.3 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.63. This means the shares are trading above this model’s fair value.

XORTX Therapeutics Inc. (NASDAQ:XRTX) closed at $2.26 USD, gaining $0.38 (20.53%) from the previous close of $1.88. The stock is currently mid-range between its 52-week high and low $1.73 and $7.05. With a market capitalization of about $629.38 thousand, XORTX Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.08). Key stats such as the average daily volume over the past year has been around 15.11 thousand shares, trading with heavier-than-usual volume. Headquartered in Calgary, AB, XORTX Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Allen Warren Davidoff, the company employs approximately 2 people and listed since September 23, 2021. XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections.

XORTX Therapeutics Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -7.63%. XORTX Therapeutics Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 26, 2026, missed forecasts by -46.14%. The prior quarter beat by -58.86%. Over the last six quarters, Apple has recorded several small beats. These include -34.48% in May 15, 2025.

Short-term trend indicators are bullishly aligned (SMA20 -6.45%, SMA50 -21.93%, SMA200 -44.83%). The stock’s 14-day RSI is 35.7 (weak momentum), while the ATR of 0.04 points to moderate volatility. The stock remains hovering near 52-week lows, trading -71.35% below its high and over 9.19% above its low. Average 10-day trading volume of 9.59 thousand shares is below the 3-month average of 15.42 thousand, indicating normal recent market interest.

XORTX Therapeutics Inc. has 5.21 million shares outstanding. The public float is 5.07 million shares, elevated short interest at 0.70% of float. This equals 35.32 thousand shares. The short ratio is 0.4 days. Institutional investors hold 4.72% of the float. Insiders own 7.83%.

XORTX Therapeutics Inc. trades at a P/E ratio of -0.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.7 suggesting the stock is closer to book value. The P/FCF stands at -0.36, also above market averages.

Our AI price prediction model suggests that XORTX Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.64%, with price expected at $2.11 by September 08, 2026, within a range of $2.03 to $2.19 3-Month Outlook: Projected fall of -40.27%, reaching $1.35 by November 23, 2026, with a range of $0.86 to $1.92. 1-Year Outlook: Projected loss of -40.71%, with price at $1.34 by August 25, 2027, within a range of $0.00 to $15.51.

XORTX Therapeutics Inc. (NASDAQ:XRTX) shares are flat 0.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows XORTX Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.88. Our AI forecast model points to short-term weakness (-6.64% over two weeks), a medium-term fall (-40.27% over three months), and a longer-term loss (-40.71% over one year), with expected trading ranges indicating moderate volatility.